Table 1 Demographic and clinical characteristics at baseline
|  | Intervention group (n = 76) | Control group (n = 72) |
|---|---|---|
Age (years) | 54.4 ± 11 | 54.6 ± 12 |
Sex | ||
 Female (%) | 45 (59) | 43 (60) |
 Male (%) | 31 (41) | 29 (40) |
Height (cm) | 172 ± 8 | 171 ± 11 |
Body composition | ||
 Weight (kg) | 78.8 ± 15.3 | 74.9 ± 15.3 |
 Fat mass (kg) | 24.6 ± 10.3 | 21.3 ± 8.4 |
 Lean body mass (kg) | 54.2 ± 11.1 | 53.6 ± 10.6 |
 Body mass index (kg/m2) | 26.9 ± 4.5 | 25.1 ± 4.7 |
 Waist-to-hip ratio | 0.90 ± 0.2 | 0.88 ± 0.1 |
Cancer entity no. (%) | ||
 Colorectal cancer | 10 (13) | 9 (12) |
 Breast cancer | 43 (57) | 41 (57) |
 Prostate cancer | 23 (30) | 22 (31) |
Dropouts no. (%) | 14 (18) | 12 (17) |
SAE nos. (hospitalizations) | 11 | 7 |
Comorbidities, no (%) | ||
 Diabetes type 2 | 4 | 2 |
 Hypertension | 23 | 17 |
 Adiposity (BMI > 30) | 16 | 11 |
 Cardiovascular diseases | 2 | 3 |
 Hypothyroidism | 13 | 15 |
 Asthma | 2 | 2 |
 Arthritis | 9 | 3 |
Cancer medication | ||
 Estrogen receptor modulator | 9 | 16 |
 Monoclonal antibody | 2 | 1 |
 Aromatase inhibitors | 8 | 4 |
 Chemotherapy medication | 3 | 2 |
Metabolic status | ||
 CRP level (mg/l)* | 1.5 (0.7; 2.5) | 1.0 (0.6; 1.9) |
 HbA1c (%) | 5.4 ± 0.4 | 5.4 ± 0.7 |
 Albumin level (g/l) | 45.0 ± 2.8 | 45.3 ± 2.5 |
 Hemoglobin level (mmol/l) | 8.5 ± 0.85 | 8.4 ± 0.8 |
 Ferritin (ng/l) | 150 ± 189 | 180 ± 199 |